About Impax Pharmaceuticals

In July 2006 Impax Laboratories launched Impax Pharmaceuticals as the company’s branded products division.

Today, Impax Pharmaceuticals is an emerging leader in the development, manufacturing and marketing of specialty CNS products utilizing our formulation expertise, unique drug delivery technologies and drug development and commercialization expertise.

The executive management team of Impax Pharmaceuticals has extensive experience developing and marketing products for CNS disorders. Our R&D team has the collective experience of developing 17 New Drug Applications (NDAs).

Drug Research and Development Strategy

Our strategy is to focus on addressing significant unmet needs, particularly in the CNS market. We typically focus on improving the clinical utility of existing molecules leveraging our proprietary technologies, following a 505(b)(2) regulatory pathway of approval. Our goal is to offer innovative products that enhance the care of patients with CNS disorders.

We are building our product portfolio through internal development, licensing, acquisition and strategic partnerships. Our R&D pipeline is focused on Parkinson’s disease and other diseases of the central nervous system.  

Commercial Partnerships

Partnerships are an important part of our strategy. We began promoting Carbartol (carbamazipine extended-release capsules) for the treatment of epilepsy and trigeminal neuralgia, in 2006 through our partnership with Shire Pharmaceuticals to start to establish our presence in the CNS market.

In 2008 we entered into an agreement with Wyeth, now a wholly owned subsidiary of Pfizer, to promote a CNS product. Our specialty sales force currently co-promotes to neurologists Pfizer’s Lyrica® (pregabalin) CV for use as adjunctive therapy for adult patients with partial onset seizures.